A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations

Clinical trial NCT07313761 · COMPLETED

Trial details

NCT number: NCT07313761
Sponsor: Amgen
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Overweight and Obesity

Start date: 2025-12-15
Primary completion: 2026-07-02
Enrollment: 349

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.